What is it about?

Grouping psychosis patients into two cognitive "biotypes" successfully predicts their real-world adaptation—such as employment, hospital readmissions, and medical follow-up—at one and three years, validating this new clinical classification

Featured Image

Why is it important?

This study breaks with the traditional idea that psychosis is a single, uniform disease. Our research previously identified two major "biotypes" across schizophrenia and bipolar disorder based on biological damage and cognitive performance. What makes this new study crucial is proving that these differences extend beyond the lab and have measurable consequences in real life. Following patients for three years, we confirmed that those in "Cluster 1" (severe cognitive and biological deficits) faced greater life barriers: shorter job tenure, more psychiatric ward admissions in the first year, and a higher likelihood of dropping out of medical follow-up by the third year. Conversely, "Cluster 2" (moderate deficits) had a better overall trajectory but showed poorer medication adherence by the third year. Validating these biotypes opens the door to moving past traditional diagnostic labels toward personalized therapies and accurate prognoses tailored to the real-world challenges of each patient profile.

Perspectives

The heterogeneity of psychotic disorders has long frustrated the search for reliable biomarkers. This study bridges fundamental neurobiology and clinical practice by showing that a cognitive biotype predicts occupational and clinical adaptation, highlighting the urgent need for routine neurocognitive assessments. Future steps must focus on tracking these functional differences from the earliest stages of the illness (first episodes) and understanding how environmental factors interact with these profiles. Ultimately, identifying a patient's biotype early on will allow for targeted preventive interventions, such as intensive vocational support for those at risk of isolation, or specific adherence strategies for more functional profiles.

Alvaro Diez
Universidad de Valladolid

Read the Original

This page is a summary of: Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance, European Archives of Psychiatry and Clinical Neuroscience, November 2022, Springer Science + Business Media,
DOI: 10.1007/s00406-022-01518-1.
You can read the full text:

Read

Contributors

The following have contributed to this page